![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA GRANTS PROGENICS AND WYETH'S DRUG FAST-TRACK STATUS
FDA GRANTS PROGENICS AND WYETH'S DRUG FAST-TRACK STATUS
July 25, 2006
The FDA has given fast-track status to a post-surgical drug being developed by Wyeth Pharmaceuticals and Progenics Pharmaceuticals, the companies said July 17.
The drug is an intravenous form of methylnaltrexone being investigated as a potential treatment for postoperative ileus, an impairment of gastrointestinal function that delays recovery from surgery and prolongs hospitalization.
Under fast-track status, the FDA allows companies to submit clinical trial data on a rolling basis instead of submitting a comprehensive one-time application. It is intended for drugs that that treat serious diseases for which there is an unmet medical need.
The two companies have plans to submit a new drug application for the intravenous form of methylnaltexone in late 2007 or early 2008.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct